Utilization of preventive services in a systemic lupus erythematosus population-based cohort: a Lupus Midwest Network (LUMEN) study.
Cancer screening
Cardiovascular risk
DXA
Diabetes
Influenza
Osteoporosis
Pneumococcal
Preventive services
Systemic lupus erythematosus
Vaccine
Zoster
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
received:
23
04
2022
accepted:
24
07
2022
entrez:
1
9
2022
pubmed:
2
9
2022
medline:
9
9
2022
Statut:
epublish
Résumé
Systemic lupus erythematosus (SLE) is a disease that can lead to damage of multiple organs and, along with certain treatments, increase the risk of developing cancer, cardiovascular disease, diabetes, osteoporosis, and infections. Preventive services are particularly important in patients with SLE to mitigate the aforementioned risks. We aimed to evaluate the trends of preventive services utilization in patients with systemic lupus erythematosus, compared with non-SLE population. All ≥19-year-old patients in the Lupus Midwest Network (LUMEN) registry, a population-based cohort, with SLE on January 1, 2015, were included and matched (1:1) by sex, age, race, and county to non-SLE comparators. Among both groups, we compared the rates of screenings for breast and cervical cancer, hypertension, hyperlipidemia, diabetes mellitus, and osteoporosis as well as immunizations. We included 440 SLE patients and 430 non-SLE comparators. The probability of breast cancer screening among women with SLE was similar to comparators (hazard ratio [HR] 1.09, 95% CI 0.85-1.39), while cervical cancer screening was lower (HR 0.75, 95% CI 0.58-0.96). Hypertension screening was higher among patients with SLE (HR 1.35, 95% CI 1.13-1.62); however, hyperlipidemia screening was similar to comparators (HR 1.16, 95% CI 0.96-1.41). Diabetes and osteoporosis screenings were more likely to be performed for SLE patients than for comparators (HR 2.46, 95% CI 2.11-2.87; and HR 3.19, 95% CI 2.31-4.41; respectively). Influenza and pneumococcal immunizations were higher among SLE patients (HR 1.31, 95% CI 1.12-1.54; and HR 2.06, 95% CI 1.38-3.09; respectively), while zoster vaccination was similar (HR 1.17, 95% CI 0.81-1.69). The trends of utilization of preventive services by SLE patients vary according to screening or vaccine compared with the general population. Considering these differences, we demonstrate an opportunity for improvement, particularly in cervical cancer, hyperlipidemia, and osteoporosis screenings and vaccinations.
Sections du résumé
BACKGROUND
Systemic lupus erythematosus (SLE) is a disease that can lead to damage of multiple organs and, along with certain treatments, increase the risk of developing cancer, cardiovascular disease, diabetes, osteoporosis, and infections. Preventive services are particularly important in patients with SLE to mitigate the aforementioned risks. We aimed to evaluate the trends of preventive services utilization in patients with systemic lupus erythematosus, compared with non-SLE population.
METHODS
All ≥19-year-old patients in the Lupus Midwest Network (LUMEN) registry, a population-based cohort, with SLE on January 1, 2015, were included and matched (1:1) by sex, age, race, and county to non-SLE comparators. Among both groups, we compared the rates of screenings for breast and cervical cancer, hypertension, hyperlipidemia, diabetes mellitus, and osteoporosis as well as immunizations.
RESULTS
We included 440 SLE patients and 430 non-SLE comparators. The probability of breast cancer screening among women with SLE was similar to comparators (hazard ratio [HR] 1.09, 95% CI 0.85-1.39), while cervical cancer screening was lower (HR 0.75, 95% CI 0.58-0.96). Hypertension screening was higher among patients with SLE (HR 1.35, 95% CI 1.13-1.62); however, hyperlipidemia screening was similar to comparators (HR 1.16, 95% CI 0.96-1.41). Diabetes and osteoporosis screenings were more likely to be performed for SLE patients than for comparators (HR 2.46, 95% CI 2.11-2.87; and HR 3.19, 95% CI 2.31-4.41; respectively). Influenza and pneumococcal immunizations were higher among SLE patients (HR 1.31, 95% CI 1.12-1.54; and HR 2.06, 95% CI 1.38-3.09; respectively), while zoster vaccination was similar (HR 1.17, 95% CI 0.81-1.69).
CONCLUSIONS
The trends of utilization of preventive services by SLE patients vary according to screening or vaccine compared with the general population. Considering these differences, we demonstrate an opportunity for improvement, particularly in cervical cancer, hyperlipidemia, and osteoporosis screenings and vaccinations.
Identifiants
pubmed: 36050780
doi: 10.1186/s13075-022-02878-8
pii: 10.1186/s13075-022-02878-8
pmc: PMC9434086
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
211Subventions
Organisme : NCCDPHP CDC HHS
ID : U01 DP006491
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002377
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG034676
Pays : United States
Organisme : CDC HHS
ID : U01 DP006491
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Arthritis Care Res (Hoboken). 2019 Jan;71(1):104-115
pubmed: 29648687
MMWR Morb Mortal Wkly Rep. 2018 Jan 26;67(3):103-108
pubmed: 29370152
Ann Intern Med. 2009 Nov 17;151(10):716-26, W-236
pubmed: 19920272
MMWR Morb Mortal Wkly Rep. 2015 Aug 7;64(30):818-25
pubmed: 26247435
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Semin Arthritis Rheum. 2010 Dec;40(3):193-200
pubmed: 20378155
Lupus. 2016 Jun;25(7):727-34
pubmed: 26811368
Ann Rheum Dis. 2015 Sep;74(9):1706-13
pubmed: 24834926
Lupus. 2013 Mar;22(3):238-44
pubmed: 23257402
Rheumatology (Oxford). 2015 May;54(5):836-43
pubmed: 25323056
Arthritis Care Res (Hoboken). 2022 Feb;74(2):179-186
pubmed: 32937019
Ann Intern Med. 2007 Dec 4;147(11):783-6
pubmed: 18056662
Int J Epidemiol. 2018 Apr 1;47(2):368-368j
pubmed: 29346555
Am J Med. 2022 Mar;135(3):286-296.e9
pubmed: 34563493
Am J Epidemiol. 2011 May 1;173(9):1059-68
pubmed: 21430193
Lupus Sci Med. 2021 Aug;8(1):
pubmed: 34433613
JAMA. 2018 Jun 26;319(24):2521-2531
pubmed: 29946735
Semin Arthritis Rheum. 2013 Oct;43(2):209-16
pubmed: 23731530
Arthritis Rheum. 2003 Nov;48(11):3159-67
pubmed: 14613278
JAMA. 2016 Nov 15;316(19):1997-2007
pubmed: 27838723
Arthritis Care Res (Hoboken). 2016 Aug;68(8):1128-34
pubmed: 26662554
Ann Intern Med. 2015 Dec 1;163(11):861-8
pubmed: 26501513
JAMA Netw Open. 2020 Mar 2;3(3):e200618
pubmed: 32150271
Ann Intern Med. 2015 Nov 17;163(10):778-86
pubmed: 26458123
Ann Rheum Dis. 2019 Jun;78(6):736-745
pubmed: 30926722
MMWR Morb Mortal Wkly Rep. 2010 Sep 3;59(34):1102-6
pubmed: 20814406
MMWR Morb Mortal Wkly Rep. 2014 Aug 22;63(33):729-31
pubmed: 25144544
J Rheumatol. 2003 Mar;30(3):493-6
pubmed: 12610807
Ann Intern Med. 2011 Mar 1;154(5):356-64
pubmed: 21242341
Nat Immunol. 2020 Jun;21(6):605-614
pubmed: 32367037
Rheumatology (Oxford). 2017 Apr 1;56(4):613-619
pubmed: 28039412
Nat Rev Dis Primers. 2016 Jun 16;2:16039
pubmed: 27306639
Ann Rheum Dis. 2022 May 16;:
pubmed: 35577385
J Rheumatol. 2018 Jan;45(1):83-89
pubmed: 29142034
Arthritis Rheumatol. 2019 Sep;71(9):1400-1412
pubmed: 31385462
Mayo Clin Proc. 2012 Feb;87(2):151-60
pubmed: 22305027
Arthritis Care Res (Hoboken). 2021 Dec;73(12):1796-1803
pubmed: 32799430
Rheumatology (Oxford). 2022 May 30;61(6):2424-2431
pubmed: 34718442
MMWR Morb Mortal Wkly Rep. 2019 Nov 22;68(46):1069-1075
pubmed: 31751323
Lupus. 2013 Mar;22(3):268-78
pubmed: 23340996
Arthritis Care Res (Hoboken). 2012 Jan;64(1):2-8
pubmed: 22213721
RMD Open. 2019 Sep 19;5(2):e001041
pubmed: 31673420
Ann Intern Med. 2016 Feb 16;164(4):279-96
pubmed: 26757170
Ann Intern Med. 2012 Jun 19;156(12):880-91, W312
pubmed: 22711081
Arthritis Care Res (Hoboken). 2021 Jan;73(1):146-157
pubmed: 31628721
Arthritis Care Res (Hoboken). 2022 May;74(5):728-732
pubmed: 34825516
J Rheumatol. 2006 Jan;33(1):45-9
pubmed: 16331804
JAMA. 2018 Aug 21;320(7):674-686
pubmed: 30140884
Arthritis Res Ther. 2010;12(3):R84
pubmed: 20462444